Seb Grocott
@sebgrocott.bsky.social
Immunology PhD Student | Crome Lab
Reposted by Seb Grocott
🎉Excited to share our recently online pre-print of our study showing human IL-10+ILC2s have cell therapy potential to improve islet transplant by suppressing graft rejection. Many thanks to all our collaborators, patients, and my supervisor, @sarahcrome.bsky.social. doi.org/10.1016/j.aj...
Redirecting
doi.org
May 26, 2025 at 12:34 PM
🎉Excited to share our recently online pre-print of our study showing human IL-10+ILC2s have cell therapy potential to improve islet transplant by suppressing graft rejection. Many thanks to all our collaborators, patients, and my supervisor, @sarahcrome.bsky.social. doi.org/10.1016/j.aj...
Reposted by Seb Grocott
🎉 New Year, New Paper! We're excited to share our latest study led by @kyletreid.bsky.social, demonstrating human IL-10-producing ILC2s can be harnessed in cell therapies. 🧬✨ www.cell.com/cell-reports...
#Immunology #Transplantation #GVHD #RegenerativeMedicine #CellTherapy #ILC2
#Immunology #Transplantation #GVHD #RegenerativeMedicine #CellTherapy #ILC2
Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses
Reid et al. report that IL-10⁺ ILC2 cell therapy inhibits graft-versus-host disease (GVHD) in humanized mice, consistent with patient studies where IL-10⁺ ILC2s are associated with protection from GVHD. Human IL-10⁺ ILC2s express CD49d and CD86 and inhibit allogeneic T cell responses via an IL-4- and IL-10-dependent mechanism. These findings support harnessing IL-10⁺ ILC2s therapeutically.
www.cell.com
January 6, 2025 at 12:29 PM
🎉 New Year, New Paper! We're excited to share our latest study led by @kyletreid.bsky.social, demonstrating human IL-10-producing ILC2s can be harnessed in cell therapies. 🧬✨ www.cell.com/cell-reports...
#Immunology #Transplantation #GVHD #RegenerativeMedicine #CellTherapy #ILC2
#Immunology #Transplantation #GVHD #RegenerativeMedicine #CellTherapy #ILC2